Zimmer Biomet Launches VANGUARD® Individualized Design Knee Replacement

WARSAW, Ind., Sept. 20, 2016 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the launch of Vanguard® Individualized Design (ID), a first-of-its-kind total knee arthroplasty (TKA) construct designed to enable a personalized fit while simplifying soft tissue preservation and balance. Traditional total knee implants feature a one-piece bearing constructed of polyethylene which is placed between the metal portions of the implant. Vanguard ID is the only TKA design to incorporate two individual polyethylene bearings with different articulations on the medial and lateral sides. The Vanguard ID’s flexible design allows surgeons to mix and match bearings of differing thickness and geometry, ensuring they can personalize their approach to accommodate and preserve natural soft tissue.

“I believe that our newly released Vanguard Individualized Design will revolutionize total knee replacement.  With the ability to fine tune the knee’s balance through the use of independent medial and lateral bearing thickness and constraint options, we will arm the surgeon with the ultimate soft tissue respecting capability,” said Todd Davis, Vice President & General Manager of the global Knee business.

The original Vanguard® Knee system, which debuted in 2003, pioneered personalization in knee replacement by offering the broadest range of available sizes.  By equipping surgeons to combine a vast number of bearings of varying thickness (up to 2 mm) and articulations to ensure a personalized feel, the Vanguard ID builds on the Vanguard knee’s legacy of enabling surgeons to create a personalized fit, while maintaining surgical simplicity and intraoperative flexibility.

“Maintaining natural ligament tension while preserving healthy soft tissue is critical not only to restore normal range of motion but to achieve patient satisfaction,” said Tom Aleto, M.D. (Missouri Orthopedic Institute, Columbia, Missouri).  “In traditional knee design, surgeons typically release healthy soft tissues in an attempt to balance the knee and maintain feasible kinematics. Because the Vanguard ID allows me to mix and match components, I am able to individually treat each compartment while maintaining healthy soft tissues.  I personally feel that, by utilizing Vanguard ID and a soft tissue respecting surgical technique, I’m achieving higher patient satisfaction.”

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes.  Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially.  For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC.  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC.  We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports.  Accordingly, such forward-looking statements speak only as of the date made.  Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this news release.

Logo – http://photos.prnewswire.com/prnh/20150624/225371LOGO


SOURCE Zimmer Biomet Holdings, Inc.

Related Links


Orthopaedic Surgeons to Use HipGrid Drone at the ICJR 2016 5th Annual Direct Anterior Approach Hip Course

SALT LAKE CITY, Sept. 14, 2016 /PRNewswire/ — This September 22-24, the International Congress for Joint Reconstruction (ICJR) will hold its 5th Annual Direct Anterior Hip Course for orthopaedic surgeons in Houston, TX. OrthoGrid Systems, Inc.’s (Salt Lake City, UT) will be in attendance at the meeting for the fourth year in a row.

OrthoGrid’s presence at the meeting has grown over the past four years. Richard Boddington, OrthoGrid CEO says, “We thank ICJR for the opportunity to showcase the efficacy of our HipGrid technology for direct anterior total hip arthroplasty. We’re thrilled to offer orthopaedic surgeons a simple, elegant solution to ease the learning curve of an already challenging procedure.”

OrthoGrid’s mix of innovative culture, emphasis on research and development, and technological advances provides a high level of ease, efficiency, and accuracy to orthopaedic surgical procedures such as total hip replacement (THR). “We look forward to meeting the surgeons attending this year’s ICJR Direct Anterior Hip Course and making their learning experience even more valuable with HipGrid,” says Mr. Boddington.

Direct anterior total hip arthroplasty (THA) has been gaining in popularity amongst surgeons and patients, as it is less invasive than standard, posterior approach total hip arthroplasty. With HipGrid, surgeons can quickly and effectively assess anatomic alignment and implant positioning in real time in the operating room using fluoroscopy and make necessary adjustments to optimize the surgical outcomes.

HipGrid’s effectiveness has been demonstrated in peer-reviewed and ongoing direct anterior THA clinical studies, which show improved acetabular cup angle, leg length, and hip offset outcomes and decreased mean surgical time with HipGrid compared to without.

“We have a unique product that marries seamlessly with the other tools required to successfully implement a direct anterior approach program, and we look forward to making it available to as many surgeons as possible who are interested in improving and standardizing their fluoroscopic technique without breaking the bank,” says Edouard Saget, OrthoGrid president.

To learn more about OrthoGrid and HipGrid Drone technology, visit OrthoGrid.com.

About OrthoGrid Systems, Inc.

OrthoGrid Systems, Inc. is a privately owned medical device company based in Salt Lake City, Utah.  Its focus is inventing more accurate and cost-effective ways to assist in proper positioning of implants and restoration of leg length when performing total hip replacement (THR). OrthoGrid supplies a growing portfolio of patented and patent-pending technologies related to intraoperative alignment using radiopaque grid patterns for orthopedic total joint arthroplasty and trauma.  Please visit company website for more information: www.OrthoGrid.com.

OrthoGrid® Systems, Inc.
Media Contact: Tonya Trest, VP of Sales and Marketing
Phone: 801-703-5866
Source: OrthoGrid Systems, Inc.

SOURCE OrthoGrid Systems, Inc.

Related Links


In Consolidated Osteosynthesis Devices Market, Players Now Feel Compelled to Look Beyond Metals for Growth

9-13-2016 – Press Release from: TMR – Research Reports

Degradable and bioabsorbable osteosynthesis devices have reached a point in their commercialization cycle where they now carry the capability to transform the future of the global osteosynthesis devices market as a whole. Although the global osteosynthesis devices market is currently dominated by devices made from non-degradable materials—mainly metals—the future clearly belongs to degradable materials. This also explains why companies have trained their focus on developing innovative materials that can heal fractures and be gradually absorbed by the body. Besides the physical benefits that come along with degradable osteosynthesis devices, the economic benefits are also making them an attractive option – mainly because they eliminate the need for a second implant removal surgery.

Research Report:
The global osteosynthesis devices market is expected to post strong gains in terms of both volume and value on account of a substantial increase in the number of osteoporosis and osteosynthesis cases reported worldwide. According to a study published by Transparency Market Research, revenue gains in the osteosynthesis devices market are expected to rise at a CAGR of 6.5% between 2015 and 2023. TMR’s valuation of the market by the end of 2023 is US$11.09 bn.
What strategies separate osteosynthesis devices market leaders from other smaller players?
Entering the global osteosynthesis devices market requires a massive economic and strategic effort for new players. The reasons for this can be illustrated with the following points:
  • DePuy Synthes alone commanded over 48.6% of the osteosynthesis devices market in 2014. The company’s formidable stake in the market was a result of DePuy (Johnson & Johnson company) joining forces with Synthes to gain a wider presence in the market.
  • The next leading player in the osteosynthesis devices market as of 2014 was Stryker Corporation, boasting nearly 24% of market revenues. The company has an expansive range of products, including but not limited to hip fixation devices and intramedullary nail devices.
  • Nearly 11.6% of the osteosynthesis devices market, in 2014, was held by Zimmer Biomet. Although the company’s product portfolio comprises numerous non-degradable osteosynthesis devices, it is focusing on developing newer materials and devices that are safety-evaluated by leading agencies.
The sizeable shares and well-established business network that the top three companies already occupy in the market leave the other companies to compete for what remains, making it difficult for new companies to make a foray into this space.
To what extent will product recalls dent the growth of the global osteosynthesis devices market?
Product recalls are arguably the biggest challenge for companies in the global osteosynthesis devices market. Besides recalls, lawsuits filed against leading players also mean that companies have to set aside appreciable portions of their revenues for legal battles and settlement fees. A case in point would DePuy Synthes’ recall of 93,000 implants in 2010. The company also had to shell out an estimated US$4 mn in settlement of lawsuits filed by patients who had undergone hip implants that had inherent problems.
Metal implants continue to be a sore spot in the overall growth strategies of leading companies and this has forced them to look for more innovative materials and osteosynthesis devices.

Categories: ,


Improving the Lives of Patients, Bioness’ StimRouter™ Neuromodulation System Currently Being Implanted to Manage Chronic Pain

VALENCIA, Calif., Sept. 7, 2016 /PRNewswire/ — Bioness, Inc., the leading provider of cutting edge, clinically supported rehabilitation therapies, today announced a series of successful StimRouter Neuromodulation System implantations to manage chronic pain conditions originating from varied peripheral neuralgias. As a minimally invasive device designed to reduce pain by specifically targeting the affected peripheral nerve, StimRouter is designed to be a cost-effective alternative to injections, ongoing medication regiments, and complex surgeries.

Nearly 100 million Americans suffer from debilitating chronic pain, which may be experienced across all areas of the body including the arm, torso and leg. Chronic pain is often secondary to a primary condition (e.g. stroke) and can also result from entrapment or compression syndromes, post-surgical complications or failed surgeries.

“For many years we have had limited solutions to help our patients manage their debilitating pain,” shared William Porter McRoberts, MD, a trained Physiatrist and Interventional Spine and Pain Management Specialist based in Fort Lauderdale, Florida. “As hard as it is to understand the impact of one’s pain, it is easy to see when relief is delivered. I’m very pleased with how well my patients are responding to the StimRouter and believe that the technology will be suitable for a greater range of patients in the future.”

StimRouter was the first FDA cleared non-drug, long-term, minimally invasive neuromodulation medical device indicated to treat chronic pain of a peripheral nerve origin. The patient controlled device is an adjunct to other modes of therapy (e.g., medications) and is being well received by patients and clinicians alike.

The StimRouter is currently being implanted at prestigious clinical institutions across the country to treat chronic peripheral nerve pain, with specific focus on the following conditions or areas:

  • Axillary nerve (e.g. post-stroke shoulder pain)
  • Ulnar nerve (e.g. cubital tunnel syndrome)
  • Ilioinguinal (e.g. post-surgical hernia complication)
  • Superior Cluneal nerve (e.g. lower back neuralgia)

“As clinicians and patients continue to look for effective and sustainable ways to treat and manage pain, it is rewarding to see patients thrive with our StimRouter technology,” shared Todd Cushman, President and CEO of Bioness. “Pain is more than just a barrier to a comfortable life and pursing employment, it can be what prevents patients from being able to seek therapy to rehabilitate an injury or illness.”

For more information on the StimRouter as well as videos of real patients sharing their StimRouter experience, please visit www.stimrouter.com.

About StimRouter Neuromodulation System
StimRouter is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive neuromodulation medical device consisting of a thin, implanted lead with conductive electrode, external pulse transmitter (EPT), and hand-held wireless patient programmer. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. StimRouter is programmed at the direction of the physician to meet patient requirements but is controlled by the patient to address the patients specific, changing pain management needs.

About Bioness Inc.
Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include external and implantable functional electrical stimulation (FES) systems, robotic systems and software-based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at www.bioness.com

Media Relations Contact Information
Next Step Communications

StimRouter™ and Bioness® are trademarks of Bioness, Inc. | www.bioness.com | Rx Only | Additional information about StimRouter can be found at www.stimrouter.com.


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/improving-the-lives-of-patients-bioness-stimrouter-neuromodulation-system-currently-being-implanted-to-manage-chronic-pain-300323378.html

Orthofix Announces First Patient Enrollment in Osteoarthritis of the Knee Study

September 12, 2016

LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix International N.V., (NASDAQ:OFIX), a diversified, global medical device company, today announced enrollment of the first patient in a study evaluating the use of pulsed electromagnetic field (PEMF) technology for osteoarthritis (OA) of the knee. This study will assess the efficacy and safety of the Company’s Physio-Stim system in reducing inflammation and restoring homeostasis of the extracellular matrix, potentially providing symptomatic relief of OA pain, reducing cartilage breakdown and stimulating new cartilage formation. If successful, this would be the first disease-modifying treatment for osteoarthritis. Preservation or restoration of joint structure together with reduction of inflammation would be expected to improve symptoms and reduce the need for surgical intervention.

The first patient in the study was enrolled by Dr. Roy Aaron, Professor at Brown University in Providence, RI. “Finding new solutions for OA of the knee is important as these patients not only suffer from pain, they often have a high level of disability from the disease and often seek costly surgical solutions,” said Dr. Aaron. “We are hopeful that active PEMF stimulation may provide us with a new non-invasive treatment approach that could help patients with knee OA avoid surgery and improve their overall quality of life.”

The OA of the knee study is a prospective, randomized, double-blind, placebo-controlled feasibility trial that will enroll approximately 150 patients who are 40 years of age or older at three sites in the U.S. These include Brown University School of Medicine in Providence, RI; Sinai Hospital of Baltimore in Baltimore, MD; and the Cleveland Clinic in Cleveland, OH. Study participants will be randomized in a two-to-one ratio to either an active or placebo control (inactive) device and followed for 12 months after initiation of treatment.

“This study demonstrates Orthofix’s vision of developing new applications for our PEMF technology,” said James Ryaby, Ph.D., Chief Scientific Officer for Orthofix. “We are proud to conduct research studies like these in order to find solutions for patients who live with disabling diseases and conditions such as OA.”

The Orthofix Physio-Stim device is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of nonunion fractures. The device uses a low-level electromagnetic field (PEMF) that helps activate and augment the body’s natural healing process. Use in the OA study is investigational and is being conducted under an Investigational Device Exemption (IDE) from the FDA. More information is available at ClinicalTrials.gov.

About Osteoarthritis of the Knee

Osteoarthritis is a common disease and one of the leading causes of disability. The Centers for Disease Control and Prevention estimate that nearly one in two people may develop symptomatic knee OA by age 85. Statistics show that in 2011 alone, there were 757,000 total knee replacement procedures performed, with OA accounting for 95 percent of these surgeries. Osteoarthritis of the knee is a degenerative, “wear-and-tear” type of arthritis where the cartilage in the knee joint gradually wears away. This painful disease most often effects people 50 years of age and older, but may occur in younger people, too. People with OA of the knee often experience pain when walking, running, bending or kneeling. They may also experience joint stiffness and swelling, making it difficult to do many everyday activities.

About Orthofix

Orthofix International N.V. is a diversified, global medical device company focused on improving patients’ lives by providing superior reconstructive and regenerative orthopedic and spine solutions to physicians worldwide. Headquartered in Lewisville, TX, the company has four strategic business units that include BioStim, Biologics, Extremity Fixation and Spine Fixation. Orthofix products are widely distributed via the company’s sales representatives, distributors and subsidiaries. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as Brown University, Sinai Hospital of Baltimore, Cleveland Clinic, Texas Scottish Rite Hospital for Children and the Musculoskeletal Transplant Foundation. For more information, please visit www.orthofix.com.

Forward-Looking Statements

This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of Orthofix and its subsidiaries, are based on management’s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. The forward-looking statements in this release do not constitute guarantees or promises of future performance. Factors that could cause or contribute to such differences may include, but are not limited to the risks described in the “Risk Factors” section of our 2015 Annual Report on Form 10-K, as well as in other reports that we file in the future. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release.


Orthofix International N.V.
Investor Relations
Mark Quick, 214-937-2924
Media Relations
Denise Landry, 214-937-2529

Post-operative use of PICO™ Single use Negative Pressure Wound Therapy improves predictability in wound healing and reduces complications following orthopaedic surgery

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the publication of new clinical evidence highlighting improved patient outcomes following orthopaedic surgery.1

A Randomised Controlled Trial (RCT) of 220 patients undergoing primary hip or knee replacement compared the use of PICO, the novel Single use Negative Pressure Wound Therapy (NPWT) system, with standard dressings on closed surgical incisions. The research took place over a 12 month period at The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust (RJAH), Shropshire, UK. Results show significant reduction in; wound exudate distribution within the dressing, the number of dressing changes and extreme length of stay in hospital amongst those patients where PICO was applied.1

Whilst Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) are commonplace procedures, reported figures of complications vary. Surgical site infection rate is suggested to be between 1-3% in the general orthopaedic population2, however UK Patient Reported Outcome Measures note that post-operative wound problems are recorded by approximately 10-13% of patients.3

Mr Sudheer Karlakki, lead RCT author and Consultant Orthopaedic Surgeon at RJAH, explains, “By introducing PICO as a prophylactic measure we have been able to demonstrate predictable wound healing following total hip and knee replacement procedures. Better wound management offers significant value to our hospital both in terms of reducing associated healthcare costs and by improving each patient’s outcome and experience.”

The impact of post-operative complications and prolonged wound exudate is serious and can lead to delayed discharge, increasing the care and cost burden to the hospital.4   The cost of any additional stay in a UK hospital is estimated at £275.00 per day, per hospital bed.1 Findings indicate that the use of PICO resulted in patients having a significantly smaller probability of experiencing excessive Length of Stay (LOS). The study showed a smaller range and spread of LOS in those patients with PICO compared to the standard dressing (1-10 days compared to 2-61 days).1   

The use of PICO resulted in a four-fold reduction in the number of patients experiencing Grade 4 distribution of wound exudate within the dressing when compared with standard wound dressing in those undergoing joint replacement.1 Prolonged wound drainage and high exudate levels increase the risk of wound complications by delaying healing, and have been associated with surgical site and deep prosthetic infections.1, 4

There was also a four-fold decrease (from 8% to 2%) in superficial surgical site complications.1 A further benefit was shown in the significant reduction in the number of total dressing changes required per patient using PICO. Fewer dressing changes may lead to greater patient comfort and less burden on nursing resource. Taking into account reduced LOS for the study group, lower wound complications, lower dressing changes and potential cost savings for wound care in the community due to reduced wound complications in the study group, the authors believes the cost of the PICO is justifiable.1

“Wound complications do not only impact the hospital, but they can have a devastating effect on a patient’s recovery,” explains Helen Griffiths, Outpatient Nurse at RJAH. “There is often a financial impact for the family as more time off work is required, not just for the patient but also their carer. High levels of wound exudate or infections can also cause embarrassment and discomfort, often resulting in significant anxiety. PICO can help prevent these issues through improved wound healing and increased patient confidence.”

While significant benefits have been demonstrated for patients across all demographics, statistical analysis suggests that the use of PICO as a prophylactic for closed surgical incision management in patients that are categorised as high risk (BMI >35, ASA >3 or, diabetics is particularly beneficial.1

The full study is published in Bone and Joint Research in August 2016 and is available on their website.

Mr Sudheer Karlakki will be presenting the results of the RCT at the European Bone and Joint Infection conference in September.



Beth Lowes or Rachel Cunningham
ROAD Communications on behalf of Smith & Nephew
+44 (0)208 995 5832

About the study

This Investigator Initiated Study (IIS) was performed at Robert Jones and Agnes Hunt Orthopaedic Hospital in which Smith and Nephew Wound Management provided funding and devices, which sought to determine whether the use of a incisional Negative Pressure Wound Therapy (PICO, Smith & Nephew) could give predictable length of stay by improved management of the incisional wound after planned primary joint replacement surgery. This was a 220 patient Randomised Controlled Trial (RCT) of PICO, compared to standard dressings. The PICO group showed an improvement in all areas investigated compared to standard care control group.

About PICO

PICO is cleared for use in hospital and homecare settings in Europe, US, Canada, and Australia. In Japan PICO is cleared for use in open wounds only.For more information about the PICO system and the NPWT portfolio of products from Smith & Nephew, please visit www.smith-nephew.com. Clinicians and patients may also refer to the 24/7 Negative Pressure Wound Therapy hotline, 0800 9155394 (UK) and 1800 303 622 (Ireland)

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management,Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2015 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

Smith & Nephew will be presenting more of the latest research on surgical site complications at WUWHS 2016. To learn more go to http://www.smith-nephew.com/wuwhs2016/.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.

◊Trademark of Smith & Nephew.

©July 2016 Smith & Nephew 75112


Zimmer Biomet Earns EPA Recognition for Converting Warsaw-Indiana Headquarters to 100-Percent Green Power

WARSAW, Ind., Sept. 7, 2016 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Warsaw, Indiana-based headquarters will be wholly powered by renewable, green energy, in compliance with the U.S. Environmental Protection Agency’s(EPA) Green Power Partnership program. Green power is zero-emissions electricity that is generated from environmentally preferable renewable resources, such as wind, solar, geothermal, biogas, eligible biomass, and low-impact hydro. Zimmer Biomet’s headquarters building will receive green power from Northern Indiana Public Service Company (NIPSCO), an approved provider of green power for the EPA’s Green Power Program, which allows homes and businesses to designate a portion, or all, of their monthly electric usage to be attributable to electricity generated by renewable energy sources.

“We are proud to partner with the EPA and NIPSCO to lead the green power revolution in Indiana by converting 100 percent of our headquarters’ power consumption to renewable energy sources,” said Robin T. Barney, Senior Vice President, Global Operations and Logistics.  “Sustainably and responsibly sourcing our electric power is a critical milestone in advancing Zimmer Biomet’s longstanding commitment to sustainability, and we hope our efforts inspire local area businesses and residents to join the EPA’s Green Power Program to collectively reduce our region’s environmental footprint.”

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Headquartered in Merrillville, Indiana, NIPSCO has proudly served the energy needs of northern Indiana for more than 100 years.  As Indiana’s largest natural gas distribution company and the second largest electric distribution company, NIPSCO serves approximately 810,000 natural gas and 460,000 electric customers across 32 counties. NIPSCO is part of NiSource’s seven regulated utility companies. NiSource is one of the largest fully regulated utility companies in the United States, serving approximately 4 million natural gas and electric customers through its local Columbia Gas and NIPSCO brands. More information about NIPSCO and NiSource is available at NIPSCO.com and NiSource.com.

For more information or to enroll in the Green Power Program, please visit NIPSCO.com/GreenPower or call 1-(800)-4NIPSCO (464-7726).

About EPA’s Green Power Partnership
The Green Power Partnership is a voluntary program that encourages organizations to use green power as a way to reduce the environmental impacts associated with electricity use. The Partnership currently has more than 1,400 Partner organizations voluntarily using billions of kilowatt-hours of green power annually. Partners include a wide variety of leading organizations such as Fortune 500® companies; small and medium sized businesses; local, state, and federal governments; and colleges and universities. For additional information, please visit www.epa.gov/greenpower.

Logo – http://photos.prnewswire.com/prnh/20150624/225371LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zimmer-biomet-earns-epa-recognition-for-converting-warsaw-indiana-headquarters-to-100-percent-green-power-300323119.html

SOURCE Zimmer Biomet Holdings, Inc.

News Provided by Acquire Media

Exactech Announces Investor Presentation at Baird Global Healthcare Conference

September 06, 2016

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for extremities, knee, hip, spine and biologics, will present to investors at the Baird 2016 Global Healthcare Conference in New York on Wednesday, September 7, 2016. The company will also host one-on-one meetings with institutional investors.

The presentation by Exactech CEO David Petty and Executive Vice President of Finance & CFO Jody Phillips will begin at 4:20 p.m. ET, and will be available via live and archived webcast at http://wsw.com/webcast/baird46/exac. The replay will be available for 90 days.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com andhttp://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.


Exactech, Inc.
Investor contacts:
Jody Phillips, 352-377-1140
Executive Vice President of Finance &
Chief Financial Officer
Hawk Associates
Julie Marshall or Frank Hawkins, 305-451-1888
Media contact:
Priscilla Bennett, 352-377-1140
Vice President, Corporate & Marketing Communication

DJO Global Announces Appointment of Mike Eklund as Chief Operating Officer and Chief Financial Officer

Sept. 6, 2016

SAN DIEGO–(BUSINESS WIRE)– DJO Global, Inc., a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced the appointment of Mike Eklund as Chief Operating Officer and Chief Financial Officer, effective September 12, 2016.

“We are pleased to announce the appointment of Mike Eklund as Chief Operating Officer and Chief Financial Officer,” said Mike Mogul, DJO’s President and Chief Executive Officer. “The Chief Operating Officer role is a new position at DJO Global, which we have created to partner in leading day to day execution and to build a laser focus on end-to-end productivity.”

Mr. Eklund joins DJO Global from Dell where he last served as the Senior Vice President, Dell / EMC Value Creation and Integration Management Office. In this role, he led the Value Creation and Integration function for the $67 Billion combination of Dell and EMC. Prior to his latest role, he served as Chief Financial Officer of Dell’s $40 Billion Client Solutions Business Unit and Global Operations organization. In this role, he was also responsible for leading Dell’s Global Productivity Transformation Office, where he developed an affordability framework to define the core business model, identifying $3 Billion of productivity improvements and executing structural and quality savings of over $300 Million.

Previously, Mr. Eklund served as Vice President of Strategy, Business Planning and Operations for Dell’s $10 Billion Enterprise Solutions Group. He brings a wealth of global experience over a 20 year career with Dell, including finance and operating and treasury roles. In addition, he completed a 3 year international assignment based in the UK, as Finance Director for Dell’s Emerging Markets business which grew significantly during his tenure.

Mr. Eklund began his career in public accounting as a staff accountant in tax and audit, followed by a two year stint in the oil and gas industry in a variety of staff accounting and finance roles. He has a bachelor’s degree in accounting and a master’s degree in business administration (MBA).

About DJO Global

DJO Global is a leading global developer, manufacturer and distributor of high-quality medical devices that provide solutions for musculoskeletal health, vascular health and pain management. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, Empi®, ProCare®, DJO® Surgical, Dr. Comfort®, Bell-Horn® and ExosTM. For additional information on the Company, please visit www.DJOglobal.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160906006532/en/


DJO Investor/Media Contact:
DJO Global, Inc.
Matt Simons
SVP Business Development and Investor Relations


Source: DJO Global, Inc.

The single protein injection which could replace the need for knee surgery for osteoarthritis sufferers

By SARA MALM – September 3, 2016

A single injection of protein harvested from a patient’s own blood may replace the need for knee surgery for osteoarthritis sufferers.

The new 20-minute procedure sees blood drawn from the patient’s arm, separated in a centrifuge, after which part of the fluid is then injected into the arthritic knee.

The surgeon who brought the treatment to the UK believes it can stop the need for keyhole surgery for osteoarthritis of the knee altogether.

Osteoarthritis is the most common type of arthritis, particularly affecting people aged 65 and over.

The degenerative condition affects the cartilage – the joint’s connective tissue – causing pain, stiffness and inflammation.

A trial study in the Netherlands published earlier this year showed that 85 per cent of patients had little to no pain in their knee six months after new procedure, which is called the NStride Autologous protein injection.

A further, larger, study based on work in Italy, Austria, Belgium and Norway, which has seen similarly positive results, is due to be published later this month.

About 55ml of blood is taken from a vein in the patient’s arm, mixed with an anticoagulant and centrifuged at high speed for 15 minutes, causing the blood to separate into three layers – a yellow blood plasma; a red blood cell concentration; and a ‘platelet-rich plasma’, a solution comprising platelet cells and some white blood cells.